Zyentia enters research collaboration with Potentia Pharmaceuticals
UK-based Zyentia, which provides solutions to protein misfolding and aggregation, has entered into a research collaboration with Potentia Pharmaceuticals, of Louisville, Kentucky. Under the terms of the collaboration Potentia will have access to Zyentia proprietary AggreSolve platform to characterise some of its compounds.
UK-based Zyentia, which provides solutions to protein misfolding and aggregation, has entered into a research collaboration with Potentia Pharmaceuticals, of Louisville, Kentucky. Under the terms of the collaboration Potentia will have access to Zyentia proprietary AggreSolve platform to characterise some of its compounds.
'This agreement with Potentia Pharmaceuticals further validates the interest and broad applicability of our AggreSolve Platform,' said Jesus Zurdo, acting ceo and research director of Zyentia.
'Zyentia is experiencing a very exciting time, with product candidates expected to enter preclinical development next year for major diseases related to protein misfolding, and we are looking at establishing research collaborations with other businesses as a way of accelerating and supporting the development of our technology platform and product pipeline.'